Table 1 General parameters of the two groups
Parameters | Group A (n = 42) | Group B (n = 42) | P-value |
|---|---|---|---|
Gender, case (%) | 0.826 | ||
Male | 18 (42.9) | 19 (45.2) | |
Female | 24 (57.1) | 23 (54.8) | |
Age, year, median (range) | 68 (43–80) | 67 (45–79) | 0.952 |
BMI, kg/m2, median, (range) | 21.5 (17.6–28.6) | 23.1 (17.3–29.7) | 0.238 |
ASA Score (%) | 0.608 | ||
2 | 11 (26.2) | 9 (21.4) | |
3 | 31 (73.8) | 33 (78.6) | |
Concomitant disease, case (%) | 32 (76.2) | 33 (78.6) | 0.794 |
Abdominal operation history, case (%) | 4 (9.5) | 3 (7.1) | 0.693 |
Preoperative biliary drainage, case (%) | 8 (19.0) | 7 (16.7) | 0.776 |
Hemoglobin, g/L, median (range) | 112.5 (86–153) | 112.0 (87–151) | 0.673 |
Total bilirubin, μmol/l, median (range) | 84.9 (10.1–440) | 79.4 (19.9–423) | 0.989 |
Direct bilirubin, μmol/l, median (range) | 64.1 (6.3–347) | 69.8 (12.8–367) | 0.733 |
Carbohydrate antigen 19–9, U/ml, median (range) | 511.5 (2.0–6021) | 493.4 (2.1–5966) | 0.834 |
Tumor size, cm, median (range) | 3.5 (2.0–5.0) | 3.3 (2.0–5.0) | 0.557 |
Tumor differentiation, case (%) | 0.903 | ||
Well | 2 (4.8) | 2 (4.8) | |
Moderate | 24 (57.1) | 22 (52.4) | |
Poor | 16 (38.1) | 18 (42.9) | |
N stage, case (%) | 0.728 | ||
N0 | 4 (9.5) | 5 (11.9) | |
N1 | 38 (90.5) | 37 (88.1) | |
Adjuvant therapy | 0.977 | ||
None | 4 (9.5) | 5 (11.9) | |
Gemcitabine | 14 (33.3) | 12 (28.6) | |
Gemcitabine+ Capecitabine | 5 (11.9) | 6 (14.3) | |
S1 | 12 (28.6) | 11 (26.2) | |
FOLFIRINOX | 7 (16.7) | 8 (19.0) |